Medicare Part B Market Analysis
Cross-industry research covering Medicare Part B across 2 market reportsspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery, Pharmaceuticals / Medical Devices — Regional Anesthesia.
Reports Covering Medicare Part B
Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR
Covers physician-administered IV biologics for TED and hospital outpatient reconstructive surgery; the IRA negotiation window currently does not cover most oculoplastic biologics given their recent approval dates, but Tepezza's LOE trajectory will introduce biosimilar price pressure by the late 2020s (Claritas model).
22%
Market Share
7.4%
Segment CAGR
Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR
Medicare Part B covers physician-administered nerve block procedures (CPT 64400–64530 series) under the physician fee schedule and hospital outpatient procedures under the OPPS. The shift of elective orthopedic procedures to ASCs under CMS's ASC Covered Procedures list expansion is increasing Part B volume capture for nerve block services previously billed under Part A DRGs. IRA drug price negotiation does not currently directly apply to small-molecule local anesthetics given generic availability, but site-neutral payment reforms threaten to compress professional fee components.
26%
Market Share
6.5%
Segment CAGR